MX385194B - Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1. - Google Patents

Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.

Info

Publication number
MX385194B
MX385194B MX2016010870A MX2016010870A MX385194B MX 385194 B MX385194 B MX 385194B MX 2016010870 A MX2016010870 A MX 2016010870A MX 2016010870 A MX2016010870 A MX 2016010870A MX 385194 B MX385194 B MX 385194B
Authority
MX
Mexico
Prior art keywords
antibody
ctla
2rbeta
combination
selective agonists
Prior art date
Application number
MX2016010870A
Other languages
English (en)
Spanish (es)
Other versions
MX2016010870A (es
Inventor
Deborah H Charych
Murali Krishna Addepalli
Seema Kantak
Steven Robert Lee
Original Assignee
Nektar Therapeutics India Pvt Ltd
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53055076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX385194(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics India Pvt Ltd, Nektar Therapeutics filed Critical Nektar Therapeutics India Pvt Ltd
Publication of MX2016010870A publication Critical patent/MX2016010870A/es
Publication of MX385194B publication Critical patent/MX385194B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2016010870A 2014-02-21 2015-02-20 Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1. MX385194B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN499DE2014 2014-02-21
IN3087DE2014 2014-10-29
PCT/IN2015/000099 WO2015125159A1 (en) 2014-02-21 2015-02-20 Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody

Publications (2)

Publication Number Publication Date
MX2016010870A MX2016010870A (es) 2016-10-26
MX385194B true MX385194B (es) 2025-03-14

Family

ID=53055076

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010870A MX385194B (es) 2014-02-21 2015-02-20 Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
MX2021009926A MX2021009926A (es) 2014-02-21 2016-08-19 Agonistas il-2rbeta-selectivos en combinacion con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009926A MX2021009926A (es) 2014-02-21 2016-08-19 Agonistas il-2rbeta-selectivos en combinacion con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.

Country Status (21)

Country Link
US (3) US10010587B2 (cg-RX-API-DMAC7.html)
EP (2) EP3834838A1 (cg-RX-API-DMAC7.html)
JP (3) JP6963385B2 (cg-RX-API-DMAC7.html)
KR (1) KR102410090B1 (cg-RX-API-DMAC7.html)
CN (1) CN106132438B (cg-RX-API-DMAC7.html)
AU (3) AU2015220408B2 (cg-RX-API-DMAC7.html)
CA (1) CA2937660A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124226T1 (cg-RX-API-DMAC7.html)
DK (1) DK3134123T3 (cg-RX-API-DMAC7.html)
ES (1) ES2872848T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210377T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053982T2 (cg-RX-API-DMAC7.html)
IL (1) IL247320B (cg-RX-API-DMAC7.html)
LT (1) LT3134123T (cg-RX-API-DMAC7.html)
MX (2) MX385194B (cg-RX-API-DMAC7.html)
PL (1) PL3134123T3 (cg-RX-API-DMAC7.html)
PT (1) PT3134123T (cg-RX-API-DMAC7.html)
RS (1) RS61661B1 (cg-RX-API-DMAC7.html)
SI (1) SI3134123T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100191T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015125159A1 (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2655409A4 (en) 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
WO2017123981A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
EP3077041B1 (en) 2013-12-05 2024-07-10 Rfemb Holdings LLC Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb)
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
PL3134123T3 (pl) 2014-02-21 2021-07-12 Nektar Therapeutics (India) Pvt. Ltd. Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1
CN106659757B (zh) 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
CA2975123A1 (en) 2015-01-30 2016-08-04 Rfemb Holdings, Llc Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
BR112018000917A2 (pt) 2015-07-16 2018-09-11 Bioxcel Therapeutics Inc abordagem inovadora para o tratamento de câncer através da imunomodulação
US11262360B2 (en) 2015-10-02 2022-03-01 Julius-Maximilians-Universität Würzburg GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
KR20250065935A (ko) 2015-11-20 2025-05-13 센화 바이오사이언시즈 인코포레이티드 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
US20200330557A1 (en) * 2016-08-19 2020-10-22 Brooklyn Immunotherapeutics Llc Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
JP2019534308A (ja) * 2016-11-10 2019-11-28 ネクター セラピューティクス 免疫療法的腫瘍治療方法
KR102619747B1 (ko) * 2017-01-10 2023-12-29 넥타르 테라퓨틱스 Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
AU2018227810A1 (en) * 2017-03-01 2019-08-29 Nektar Therapeutics Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EP3628010A4 (en) * 2017-05-02 2021-02-17 Nektar Therapeutics IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE
RU2745451C1 (ru) 2017-05-25 2021-03-25 Инститьют Фор Бейсик Сайенс Антитела к человеческому интерлейкину-2 и их применение
US11542312B2 (en) * 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
US12030940B2 (en) 2017-08-17 2024-07-09 Nektar Therapeutics Immunotherapeutic tumor treatment method
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
KR20200084880A (ko) 2017-11-06 2020-07-13 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
US20210154277A1 (en) * 2017-11-07 2021-05-27 Nektar Therapeutics Immunotherapeutic combination for treating cancer
JP2021502423A (ja) * 2017-11-13 2021-01-28 バイオエクセル セラピューティクス，インコーポレイテッド 免疫系の複数のアームを修飾することによってがんを治療するための方法及び組成物
EP3713592A4 (en) 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University INTERLEUKIN-2 PARTIAL AGONISTS
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
JP7445597B2 (ja) 2018-02-15 2024-03-07 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びそれらの塩、組成物、ならびにそれらの使用方法
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
MA52662A (fr) * 2018-03-28 2021-02-17 Ascendis Pharma Oncology Div A/S Conjugués d'il-2
IL278615B1 (en) 2018-05-14 2025-10-01 Werewolf Therapeutics Inc Activatable interleukin 12 polypeptides and methods of using them
ES2955511T3 (es) 2018-05-14 2023-12-04 Werewolf Therapeutics Inc Polipéptidos de interleucina 2 activables y métodos de uso de los mismos
WO2020095184A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combinations for treating cancer
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
PE20211284A1 (es) 2018-11-16 2021-07-19 Bristol Myers Squibb Co Anticuerpos anti-nkg2a y usos de los mismos
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
EP4058471A1 (en) 2019-11-14 2022-09-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CA3166509A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
AU2021280245A1 (en) * 2020-05-26 2022-12-08 Regeneron Pharmaceuticals, Inc. Methods of treating cervical cancer by administering a PD-1 inhibitor
US12428461B2 (en) 2020-06-03 2025-09-30 Ascendis Pharma Oncology Division A/S Treating cancer with a conjugate comprising an IL-2 moiety
WO2022098954A1 (en) 2020-11-06 2022-05-12 Nektar Therapeutics Tlr agonist compounds and related cancer immunotherapy methods
EP4243928A1 (en) 2020-11-10 2023-09-20 CatalYm GmbH Anti-gdf15 antibody and a dosage regimen for the treatment of cancer
EP4566674A3 (en) 2020-12-28 2025-08-06 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
US20240269293A1 (en) * 2021-03-29 2024-08-15 Beijing Xuanyi Pharmasciences Co., Ltd. Protein-macromolecule conjugates and methods of use thereof
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202313679A (zh) * 2021-06-03 2023-04-01 美商欣爍克斯公司 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
AU2022306974A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20250332252A1 (en) 2022-06-02 2025-10-30 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000213A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
CN101084012A (zh) * 2004-05-20 2007-12-05 津莫吉尼蒂克斯公司 使用il－21和单克隆抗体疗法治疗癌症的方法
EP1896582A4 (en) * 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
JP5081820B2 (ja) 2005-06-16 2012-11-28 ネクター セラピューティックス 分解性結合を有する複合体と該複合体の調製に有益なポリマー試薬
MX358399B (es) 2010-11-12 2018-08-16 Nektar Therapeutics Conjugados de un resto de interleucina-2 y un polímero.
EP2638395A4 (en) 2010-11-12 2016-06-01 Endocyte Inc METHOD FOR TREATING CARCINOMA
KR20140038382A (ko) * 2011-03-10 2014-03-28 프로벡투스 파마슈티컬스 인코포레이티드 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제
PL3134123T3 (pl) * 2014-02-21 2021-07-12 Nektar Therapeutics (India) Pvt. Ltd. Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1

Also Published As

Publication number Publication date
MX2021009926A (es) 2021-09-21
SMT202100191T1 (it) 2021-05-07
HRP20210377T1 (hr) 2021-04-16
CA2937660A1 (en) 2015-08-27
CN106132438A (zh) 2016-11-16
IL247320B (en) 2022-09-01
LT3134123T (lt) 2021-04-12
EP3134123B1 (en) 2021-02-17
JP2017506264A (ja) 2017-03-02
AU2015220408A1 (en) 2016-08-11
IL247320A0 (en) 2016-09-29
AU2022203550A1 (en) 2022-06-16
JP2019077723A (ja) 2019-05-23
PL3134123T3 (pl) 2021-07-12
US20200368321A1 (en) 2020-11-26
JP2021073296A (ja) 2021-05-13
WO2015125159A1 (en) 2015-08-27
HUE053982T2 (hu) 2021-08-30
RS61661B1 (sr) 2021-04-29
MX2016010870A (es) 2016-10-26
US10010587B2 (en) 2018-07-03
US20180344810A1 (en) 2018-12-06
JP6963385B2 (ja) 2021-11-10
KR102410090B1 (ko) 2022-06-16
SI3134123T1 (sl) 2021-08-31
AU2020213296A1 (en) 2020-08-27
ES2872848T3 (es) 2021-11-02
PT3134123T (pt) 2021-03-22
DK3134123T3 (da) 2021-04-06
KR20160122748A (ko) 2016-10-24
CN106132438B (zh) 2020-03-03
AU2015220408B2 (en) 2020-05-07
EP3834838A1 (en) 2021-06-16
US20170128539A1 (en) 2017-05-11
EP3134123A1 (en) 2017-03-01
CY1124226T1 (el) 2022-05-27
US10786552B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
MX385194B (es) Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2016007972A (es) Metodos para tratar canceres con antagonistas de union al eje pd-1 y taxanos.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CL2017003427A1 (es) Anticuerpos para cd40
MX2017004708A (es) Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
AR102712A1 (es) Agonistas parciales del receptor de insulina
CL2015002932A1 (es) Inhibidores de proteína quinasa
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CL2016000922A1 (es) Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2016012368A (es) Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX374290B (es) Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer.
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
MX380557B (es) Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm).